(Date:7/24/2008)... Calif., July 24 /- Poniard...maceutical company focused,on oncology, today anno...ss,the Company,s second quarter results and provid...linical development plan for picoplatin, the,Compa... chairman and chief,executive officer, Ronald A. M...
(Date:7/24/2008)... 24 /- Cara Therapeutics, Inc.,announ...dditional funding,to its original $24 million Seri...und was led by new investor, Devon Park Bioventure...ations. Previous investors participating,in the ro...hi International,Corporation and Wistar Morris. In...
(Date:7/24/2008)...ly 24 /- Sagent Pharmaceuticals, Inc....y, today announced that it,has launched ceftazidim...um, beta-lactam antibiotic. Sagent will offer ceft...acy bulk package vials. According to,IMS data, 200...tes were,approximately $45.7 million., "Sagent is...
(Date:7/24/2008)...- Monsanto Company (NYSE:,M...y approvals for Roundup,Ready 2 Yield(TM) soybeans..., the company noted the European Food Safety Autho...on concluding Roundup Ready 2 Yield is,safe for im...ns are the,second generation of the popular Roundu...
Breaking Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Cara Therapeutics Secures $12.3 Million in Series C Extension Financing 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch 2...ses today are focused on being profitable and prod...days, months and years, you,ll see an increase in ...ze businesses, as well as mid-to-large-size commer...orate technology to add efficiency to their busine...rs. , ,There are several new federal and state r...
...EE Catalyst International, a global provider of s...panded its suite of platform-independent SCE appli...E solution suite to meet customers, increasing dem...lier to end user, regardless of platform or bounda...talyst. , ,Catalyst has adopted Open Application ...
... 13th straight year, Wisconsin scored an A for eco...ise Development released its annual report card on... as glowing, as the Wisconsin Technology Networks...ewed concerns about the states ability to foster e...tplace. , ,Wisconsin is an innovative state. It ha...
...N, WI Nearly 60 people heard UW-Madison professor...lopment manager David Matthias stress the importan...eting of the Wisconsin Innovation Network (WIN) Fo...tion is the membership subsidiary of the Wisconsin...-profit science and technology advisor to the gove...
Other Biology Technology:Doing it Right: Business IT Fusion for the Future 2Doing it Right: Business IT Fusion for the Future 3Grow Wisconsin Should Help Tutor Wisconsin on Economic Growth 2WIN Northeast Wisconsin Chapter Launched for Regions Entrepreneurs 2(Date:7/23/2008)...tudy Finds Some Areas of the Body Have Greater Con...., July 23 /PRNewswire-USNewswire/ -- Fat removed,...osuction was found to be,an excellent source of st...n other areas of the body, reports a Brazilian-bas...rgery(R), the official medical journal of the,Amer...
(Date:7/22/2008)...NE, Australia, July 22 /- F...terday, the Board of Progen,Pharmaceuticals Limite...,had discontinued the PI-88 phase 3 study in liver...to develop its existing portfolio of compounds and...nal compounds and,opportunities through Merger & A...
(Date:7/22/2008)... Meeting to Discuss Development Plan Completed Suc...irstCall/ -- Amarin Corporation,plc (NASDAQ: AMRN...ith,officials at the U.S. Food and Drug Administra...op AMR101 for the treatment of,hypertriglyceridemi...ceeding to Phase 3 with AMR101 in hypertriglycerid...
(Date:7/22/2008)...ffrey Allan Will Stress the Importance to Patients... Approval Pathway, RICHMOND, Va., July 22 /PRNews... developer of follow-on biologics and biopharmaceu..., CEO of Insmed, will present at a,Congressional b...significant need for establishing an approval path...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Protecting Productivity at the Worksite in Challenging Times 10589 1Protecting Productivity at the Worksite in Challenging Times 10589 2Oncolytics Biotech Inc Proceeds to Full Enrolment in U S Phase II Sarcoma Clinical Trial 2875 1Oncolytics Biotech Inc Proceeds to Full Enrolment in U S Phase II Sarcoma Clinical Trial 2875 2Oncolytics Biotech Inc Proceeds to Full Enrolment in U S Phase II Sarcoma Clinical Trial 2875 3The HLA DRB1 gene and premature death in rheumatoid arthritis 10584 1The HLA DRB1 gene and premature death in rheumatoid arthritis 10584 2The HLA DRB1 gene and premature death in rheumatoid arthritis 10584 3New adhesive mimics gecko toe hairs 2870 1New adhesive mimics gecko toe hairs 2870 2New adhesive mimics gecko toe hairs 2870 3...TTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Ther...ase 1/2 clinical data with INGN,241, the Company,s...r agent, in patients with advanced solid tumors., ...ay at the,annual meeting of the American Society o...al, INGN 241 induced killing in all treated,tumors...
...TRÉAL, June 1, 2007 – Thallion Pharma...liminary data from its Phase,I/II clinical trial i...was published in abstract form as part of the Amer...eting in Chicago,Illinois. In the Phase I dose es...lorectal, two ovarian, one duodenal and one,glioma...
Other Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3